Prognostic value of serum uric acid and tumor response to induction chemotherapy in locally advanced nasopharyngeal carcinoma

Table 2 Multivariate analyses of independent significance of experimental intervention on clinical outcome

Variables	OS(42/341)		PFS(63/341)		DMFS(49/341)
Variables	HR (95% CI)	P	HR (95% CI)	P	HR (95% CI)	P
Gender (male vs female)	1.053 (0.546–2.031)	0.877	0.904 (0.518–1.578)	0.723	0.737 (0.384–1.412)	0.357
Age (≤50 vs >50)	2.039 (1.092–3.807)	0.025	1.512 (0.918–2.492)	0.105	1.342 (0.761–2.367)	0.310
Pathological type (WHO I-II vs WHO III)	2.295 (0.361–14.583)	0.379	1.961 (0.531–7.246)	0.313	1.532 (0.420–5.588)	0.518
T stage (T1-T2 vs T3-T4)	1.329 (0.944–1.870)	0.103	1.123 (0.866–1.457)	0.382	1.129 (0.838–1.520)	0.425
N stage (N0–1 vs N2–3)	1.766 (1.186–2.630)	0.005	1.378 (0.990–1.920)	0.058	1.634 (1.117–2.391)	0.011
Chemotherapy cycle (≤3 vs >3)	2.381 (0.910–6.226)	0.077	1.747 (0.830–3.676)	0.142	1.808 (0.767–4.264)	0.176
SUA level (≤327 vs >327)	2.385 (1.208–4.707)	0.012	1.658 (0.989–2.779)	0.055	1.744 (0.964–3.156)	0.066
Tumor response to IC (CR/PR vs SD/PD)	1.915 (1.044–3.648)	0.036	2.381 (1.408–3.816)	0.001	2.764 (1.554–4.851)	0.001

Abbreviations: CI confidence interval, CR complete response, DMFS distant metastasis-free survival, HR hazard ratio, IC induction chemotherapy, OS overall survival, PD disease progression, PFS progression-free survival, PR partial response, SD stable disease, SUA serum uric acid

ISSN: 1471-2407